AMRC Consultation 2025
Defining and demonstrating quality in multisite clinical research corporations (MCRCs)
Findings from AMRC’s industry consultation on how quality is defined, assessed, and recognized in practice.
Quality is one of the most talked-about concepts in clinical research, yet one of the least consistently defined or assessed in practice. Multisite organizations are delivering speed, predictability, and strong operational performance at scale, but those outcomes are not always recognized as indicators of quality.
To better understand why, AMRC conducted an industry consultation bringing together perspectives from Sponsors, CROs, multisite organizations, and operational and quality leaders. The findings reveal where assumptions about quality still dominate decision-making, where performance data is being overlooked, and what needs to change if the industry is serious about recognizing quality based on how trials are actually delivered.
This report captures those insights and sets out the implications for how quality should be defined, assessed, and recognized going forward.
How can you help drive change?
The consultation findings helped to inform AMRC’s 2026 working groups, which will bring together industry professionals to develop practical approaches to shared challenges around quality assessment and recognition.
Download the consultation report
Questions About the Report?
AMRC will discuss the consultation findings during a live webinar on January 29 at 1:00 pm ET. The session will explore what the findings mean for industry stakeholders and how they inform AMRC’s advocacy priorities for 2026.
